Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.36 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.35 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.34 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.34 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.33 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.33 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.33 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27639943 | 1.00 | GSR (0.46) | GSRSLC7A5SLC1A2SLC1A3SLC1A1 | |
| SCHEMBL2887202 | 0.87 | GSR (0.53) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| SCHEMBL27814766 | 0.83 | GSR (0.46) | GSRRNPEPCPB2 | |
| SCHEMBL18613506 | 0.81 | SLC7A5 (0.41) | SLC7A5SLC1A2SLC1A3SLC1A1RNPEP | |
| SCHEMBL15757064 | 0.79 | SLC7A5 (0.43) | SLC7A5SLC1A2SLC1A3SLC1A1RNPEP | |
| Hydrochloric Acid SCHEMBL15512475 | 0.78 | GSR (0.46) | GSRSLC7A5SLC1A2SLC1A3SLC1A1 | |
| SCHEMBL28624838 | 0.78 | GSR (0.45) | GSRRNPEPTHRBCPB2 | |
| SCHEMBL8931572 | 0.78 | GSR (0.60) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| SCHEMBL5556166 | 0.78 | GSR (0.60) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| SCHEMBL18043461 | 0.77 | GSR (0.51) | GSRRNPEPTHRBGNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103597071-A | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS INC | 2014-02-19 | — | — | CN | claimed |
| EP-2661266-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | Elcelyx Therapeutics, Inc. (US) | 2013-11-13 | — | — | EP | claimed |
| WO-2012094636-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ELCELYX THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | WO | claimed |
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2024-04-04 | — | — | US | disclosed |
| US-11758933-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2023-09-19 | — | — | US | disclosed |
| EP-3368542-B1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2022-06-22 | — | — | EP | disclosed |
| US-11357246-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2022-06-14 | — | — | US | disclosed |
| US-20210227863-A1 | HIGH INTENSITY SWEETENERS | SENOMYX, INC. | 2021-07-29 | — | — | US | disclosed |
| EP-3356356-B1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | FIRMENICH INCORPORATED (US) | 2021-05-26 | — | — | EP | disclosed |
| EP-3763419-A1 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | Anji Pharma (US) LLC (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-2661266-B1 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ANJI PHARMA (US) LLC (US) | 2020-09-16 | — | — | EP | disclosed |
| WO-2012094636-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ELCELYX THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | WO | disclosed |
| WO-2012054528-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ELCELYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| US-20110177545-A1 | G-PROTEINS | GIVAUDAN SA (CH) | 2011-07-21 | — | — | US | disclosed |
| US-7919236-B2 | G-proteins | GIVAUDAN SA (CH) | 2011-04-05 | — | — | US | disclosed |
| EP-1581555-B1 | CHIMERIC ALPHA Q-GUSTDUCIN G-PROTEINS | GIVAUDAN SA (CH) | 2008-04-30 | — | — | EP | disclosed |
| US-20060275765-A1 | G-proteins | GIVAUDAN SA (CH) | 2006-12-07 | — | — | US | disclosed |
| CN-1726224-A | Chimeric alpha Q-gustducin G-proteins | GIVAUDAN SA (CH) | 2006-01-25 | — | — | CN | disclosed |
| EP-1581555-A2 | G-PROTEINS | Givaudan SA (CH) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004055048-A2 | CHIMERIC ALPHA Q-GUSTDUCIN G-PROTEINS | GIVAUDAN SA (CH) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | TAS2R40, TAS2R60, TAS1R1 | GSR 2160/4885SLC7A5 61/4885SLC1A2 412/4885 |
| US-11357246-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | GSR 2160/4885SLC7A5 61/4885SLC1A2 412/4885 |
| US-20210227863-A1 | HIGH INTENSITY SWEETENERS | TAS2R40, TAS2R60, TAS1R1 | GSR 2160/4885SLC7A5 61/4885SLC1A2 412/4885 |
| US-11758933-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | GSR 2160/4885SLC7A5 61/4885SLC1A2 412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.